HOMA2-B

1. Orforglipron increases HOMA2-B in humans.

   “treatment with OFG was associated with statistically significant increases from baseline in HOMA2-B in both groups”

   Human trialin both groups72-week

   Orforglipron and Markers of Insulin Sensitivity and Beta-Cell Function by Prediabetes Status in Adults with Obesity: A Post Hoc Analysis of the ATTAIN-1 Trial

   ADA Scientific Sessions 2026 abstract·5 Jun 2026

More on Orforglipron

1. Severe insulin resistant diabetes increases HOMA2-B in humans (42.2, 95%CI: 42.1, 42.3).

   “and HOMA2-%B (42.2, 95%CI: 42.1, 42.3).”

   Humansin five years before diagnosis, relative to those without T2D

   Metabolic Trajectories Preceding Diagnosis of Type 2 Diabetes Subtypes in Cohort Studies from the United States

   ADA Scientific Sessions 2025 abstract·13 Jun 2025

More on Severe insulin resistant diabetes

1. Severe insulin-deficient diabetes decreases HOMA2-B in humans (-84.5, 95%CI: -84.6, -84.3).

   “decreases in HOMA2-%B (-84.5, 95%CI: -84.6, -84.3)”

   Humansin five years before diagnosis, relative to those without T2D

   Metabolic Trajectories Preceding Diagnosis of Type 2 Diabetes Subtypes in Cohort Studies from the United States

   ADA Scientific Sessions 2025 abstract·13 Jun 2025

More on Severe insulin-deficient diabetes